Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | NCF1 | P14598 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31185124 | 1.00 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| Quinoline SCHEMBL28850528 | 0.89 | ALDH1A1 (0.61) | CYSLTR1CYSLTR2CYP1A2PDE10AGPBAR1 | |
| SCHEMBL5025561 | 0.83 | PDE10A (0.50) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL30879956 | 0.81 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL3267444 | 0.81 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL2913941 | 0.81 | PDE10A (0.61) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL4938792 | 0.79 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL6798820 | 0.77 | CYSLTR2 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL3294465 | 0.77 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL498405 | 0.77 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4790797-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-20090098663-A1 | NOVEL WATER-SOLUBLE NANOCRYSTALS COMPRISING A POLYMERIC COATING REAGENT, AND METHODS OF PREPARING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-04-16 | — | — | US | claimed |
| US-20090042032-A1 | NOVEL WATER-SOLUBLE NANOCRYSTALS COMPRISING A LOW MOLECULAR WEIGHT COATING REAGENT, AND METHODS OF PREPARING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-02-12 | — | — | US | claimed |
| JP-2008540726-A | — | — | 2008-11-20 | — | — | JP | claimed |
| EP-1883819-A1 | NOVEL WATER-SOLUBLE NANOCRYSTALS COMPRISING A POLYMERIC COATING REAGENT, AND METHODS OF PREPARING THE SAME | Agency for Science, Technology and Research (SG) | 2008-02-06 | — | — | EP | claimed |
| EP-1883820-A1 | NOVEL WATER-SOLUBLE NANOCRYSTALS COMPRISING A LOW MOLECULAR WEIGHT COATING REAGENT, AND METHODS OF PREPARING THE SAME | Agency for Science, Technology and Research (SG) | 2008-02-06 | — | — | EP | claimed |
| WO-2006118543-A1 | NOVEL WATER-SOLUBLE NANOCRYSTALS COMPRISING A LOW MOLECULAR WEIGHT COATING REAGENT, AND METHODS OF PREPARING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-11-09 | — | — | WO | claimed |
| WO-2006118542-A1 | NOVEL WATER-SOLUBLE NANOCRYSTALS COMPRISING A POLYMERIC COATING REAGENT, AND METHODS OF PREPARING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-11-09 | — | — | WO | claimed |
| US-20040126778-A1 | Isolation of dna molecules | CYTIVA BIOPROCESS R&D AB (SE) | 2004-07-01 | — | — | US | claimed |
| EP-1379645-A2 | ISOLATION OF DNA MOLECULES USING MERCAPTO-ARYL LIGANDS | Amersham Biosciences AB (SE) | 2004-01-14 | — | — | EP | claimed |
| WO-2002083893-A2 | ISOLATION OF DNA MOLECULES USING MERCAPTO-ARYL LIGANDS | AMERSHAM BIOSCIENCES AB (SE) | 2002-10-24 | — | — | WO | claimed |
| JP-63183563-A | — | — | None | — | — | JP | disclosed |
| US-20220144747-A1 | SHIKIMATE ANALOGUES AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-05-12 | — | — | US | disclosed |
| US-20200172677-A1 | STABILIZATION OF NOBLE METAL CATALYSTS | WACKER CHEMIE AG (DE) | 2020-06-04 | — | — | US | disclosed |
| EP-3612584-B1 | STABILIZATION OF NOBLE METAL CATALYSTS | WACKER CHEMIE AG (DE) | 2020-05-27 | — | — | EP | disclosed |
| JP-S63183563-A | 2-QUINOLYLMETHYL=SULFIDE DERIVATIVE AND PRODUCTION THEREOF | MECT CORP | 1988-07-28 | — | — | JP | disclosed |
| EP-0014745-B1 | CURING AGENT FOR POLYEPOXIDES, CURABLE EPOXY RESIN COMPOSITIONS, HARDENED PRODUCTS THEREFROM AND PROCESS FOR CURING A POLYEPOXIDE | DIAMOND SHAMROCK CORPORATION (US) | 1983-05-25 | — | — | EP | disclosed |
| EP-0075827-A2 | Polyepoxide curing by polymercaptans plus catalytic co-curing agents | DIAMOND SHAMROCK CHEMICALS COMPANY (US) | 1983-04-06 | — | — | EP | disclosed |
| EP-0014745-A1 | Curing agent for polyepoxides, curable epoxy resin compositions, hardened products therefrom and process for curing a polyepoxide | DIAMOND SHAMROCK CORPORATION (US) | 1980-09-03 | — | — | EP | disclosed |
| US-4177173-A | INFUSIBLE FILMS, CASTINGS OR ADHESIVES | DIAMOND SHAMROCK CORPORATION (US) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144747-A1 | SHIKIMATE ANALOGUES AND METHODS OF USE | GRIK5, GRIK1, GRIK3 | CYSLTR1 724/4885CYSLTR2 769/4885CYP1A2 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.